Introduction
Thyroid hormones have an important role in development, metabolism and energy homeostasis. The secretion of thyroid hormones is controlled by the hypothalamus-pituitary-thyroid axis. The main thyroid hormone product is thyroxine (T4), whereas triiodothyronine (T3) is produced in smaller amounts. Plasma levels of T4 and T3 are regulated by a feedback mechanism, in which hypothalamic thyrotrophin-releasing hormone (TRH) stimulates the synthesis and release of thyrotrophin (TSH) by the anterior pituitary, thus stimulating the secretion of T4 and T3 by the thyroid gland. T3 inhibits the synthesis and secretion of TRH and TSH to complete the feedback loop. T4 and T3 activity in many tissues is regulated by the selenoenzyme family of iodothyronine deiodinases. The deiodination of T4 forms T3, the most metabolically active thyroid hormone, and reverse T3, which is thought to be hormonally inactive and possibly inhibitory on T3 activity at cellular level. 1 Thyroid disorders are among the most prevalent of medical conditions, especially in women. Hypothyroidism is an insidious condition with significant morbidity and the subtle and non-specific symptoms and signs may be mistakenly attributed to other illnesses, particularly in postpartum women and the elderly. In iodine-replete communities, the cause is normally either chronic autoimmune disease (atrophic autoimmune thyroiditis) or goitrous autoimmune thyroiditis (Hashimoto's thyroiditis) or destructive treatment for hyperthyroidism, which may account for up to one-third of cases of hypothyroidism in the community. 2 The earliest biochemical abnormality in hypothyroidism is an increase in serum TSH concentration associated with normal serum free T4 and free T3 concentrations (subclinical hypothyroidism), followed by a decrease in serum free T4 concentration, at which stage most patients have symptoms and benefit from treatment (overt hypothyroidism). In the UK, the prevalence of spontaneous hypothyroidism is between 1 and 2%, and it is more common in older women and 10 times more common in women than in men. Epidemiological studies in the UK 3 have found that 8% of women (10% of women over 55 years of age) and 3% of men had subclinical hypothyroidism. Subclinical hypothyroidism can progress to overt hypothyroidism, particularly if anti-thyroid antibody positive.
Hyperthyroidism has a significant short-term morbidity and long-term morbidity and mortality. The most common causes of hyperthyroidism in iodine-replete communities are autoimmune Graves' disease and toxic multinodular goitre. The rarer causes include excessive thyroxine replacement, an autonomously functioning thyroid adenoma or thyroiditis. 2 The prevalence of thyrotoxicosis in women is between 0.5 and 2%, and it is also 10 times more common in women than in men. Subclinical hyperthyroidism is defined as a low serum TSH concentration and normal serum free T4 and free T3 concentrations. This pattern of biochemistry may reflect mild thyroid hormone excess but may also reflect hypothalamic or pituitary disease, non-thyroidal illness or ingestion of drugs that inhibit TSH secretion. The reported overall prevalence ranges from 0.5 to 6.3%, with men and women over 65 years having the highest prevalence; approximately half of them are taking levothyroxine.
The prevalence of unsuspected overt thyroid disease is low, but a substantial proportion of subjects tested will have evidence of thyroid dysfunction, usually subclinical hypothyroidism. In the absence of the confounding effects of non-thyroidal illness or drugs, a normal serum TSH concentration has a high predictive value in ruling out thyroid disease in healthy subjects. In unselected populations, measurement of serum TSH has a sensitivity of 89-95% and a specificity of 90-96% for overt thyroid dysfunction, compared with cases confirmed by history, examination and additional testing. Normal serum TSH concentrations are found in some patients with hypothyroidism caused by pituitary or hypothalamic disease, but both these situations are rare.
The introduction of assays for serum TSH sensitive enough to distinguish between normal and low concentration allowed subjects with subclinical thyroid disease to be identified. Subclinical hyperthyroidism and subclinical hypothyroidism are common clinical entities in current practice. The diagnosis of subclinical thyroid disease is based on the sensitivity of the hypothalamic-pituitary-thyroid axis. Changes in the serum concentration of free T4 and free T3 result in negative feedback and logarithmic changes in serum TSH concentration. Even changes in free T4 and/or free T3 levels within the laboratory reference range may lead to changes in the serum TSH level outside its reference range. The management of subclinical thyroid disease especially in asymptomatic patients is controversial. In this article, we will discuss diagnosis, causes, epidemiology and clinical implications of subclinical hyperthyroidism and subclinical hypothyroidism.
Definition
Unlike many other clinical conditions, the definition in subclinical thyroid diseases is biochemical. Serum TSH is the first-line diagnostic test. The reference range for serum TSH levels in thyroid disease free individuals is typically cited as between 0.4-4.0 mIU/l. [4] [5] [6] The reference range varies in different ethnic communities, pregnancy and by age. It has been reported that serum TSH distribution progressively shifts towards higher concentration with age. Some studies recommend age-specific serum TSH reference range to avoid over diagnosis of subclinical hypothyroidism. 7 Subclinical hyperthyroidism is defined as low serum TSH but normal free T4 and T3, in the absence of hypothalamic or pituitary disease, non-thyroidal illness or ingestion of drugs that inhibit TSH secretion such as glucocorticoids or dopamine. Subclinical hypothyroidism is defined as a raised serum TSH above the reference range with a normal free T4 and T3.
Thyroid function in pregnancy
The diagnosis of subclinical thyroid disease during pregnancy needs understanding of changes of thyroid physiology that are reflected in altered thyroid function tests. The major changes in thyroid function during pregnancy are due to an increase in serum thyroxine-binding globulin (TBG) concentrations and stimulation of the TSH receptor by human chorionic gonadotropin (hCG). The use of trimester-specific reference ranges for serum TSH and method and trimester-specific reference ranges for serum free T4 are now recommended. 8 The reference range for serum TSH levels is lower particularly in the first trimester of pregnancy, i.e. both the lower normal limit and the upper normal limit of serum TSH are decreased by about 0.1-0.2 and 1.0 mIU/l, respectively, compared with the customary serum TSH reference interval of 0.4-4.0 mIU/l of non-pregnant women. This observed decrease in serum TSH during the first trimester is transient, apparently related to serum hCG levels, which are highest early in gestation. [9] [10] [11] The downward shift of TSH is more prominent in multiple pregnancies where the level of hCG are higher. In a small percentage of women, serum TSH can be completely suppressed (<0.01 mIU/l) and yet still represent a normal pregnancy.
Thyroid function in non-thyroidal illness
Assessment and interpretation of thyroid functions in patient with nonthyroidal illness is challenging especially among those hospitalized in intensive care. Many patients have low serum concentrations of T4 and T3 as well as serum TSH. These biochemical abnormalities were previously classified as the sick euthyroid syndrome, but there has been some evidence that they may have acquired transient central hypothyroidism. 12 Isolated alterations in serum TSH concentrations (either slightly low 0.10-0.30 mIU/l or high 5-20 mIU/l) occur in about 15% of such patients due to altered TSH secretion in response to non-thyroidal illness or drugs. About 2-3% of hospitalized patients have serum TSH concentrations that are suppressed (<0.10 mIU/l) or elevated (>20 mIU/l) but less than half will have an underlying thyroid disorder. In a systemic review of screening patients admitted to acute care and geriatric hospitals, ∼25% of patients with low serum TSH (<0.1 mIU/l) proved to have hyperthyroidism. 13 An accurate diagnosis can be achieved if clinical indications for measuring thyroid function exist, an accurate drug history is taken, the abnormal serum TSH is subsequently confirmed and there is a reciprocal change in free T4. The testing of hospital in-patients, predominantly elderly women, might be expected to reveal a higher proportion of unsuspected hypothyroidism, but this is not supported by the available studies, which confirm a prevalence of 2%. Unless clinically indicated, caution is also required in the investigation of thyroid function in acute psychiatric disturbances and clinical depression, since non-thyroidal illness and medication that affects thyroid function tests are both common and may prompt inappropriate intervention. Routine thyroid function testing in seriously ill patients is, therefore, not recommended unless there is a strong clinical suspicion of thyroid dysfunction. If suspected, serum TSH alone is insufficient for the evaluation. Almost all patients with subnormal but detectable serum TSH will be euthyroid when reassessed after recovery from their illness. The majority of patients with above normal serum TSH values are in the recovery phase of a non-thyroidal illness and will also recover to normal and do not have permanent primary thyroid failure.
Subclinical hyperthyroidism

Causes
The causes of subclinical hyperthyroidism can be divided broadly into two subgroups: exogenous and endogenous (Table 1) . Exogenous subclinical hyperthyroidism results from thyroid hormone replacement therapy. It may be intentional for example in patients post-treatment for thyroid malignancy to keep the serum TSH suppressed or due to over treatment. In the Colorado study 40% of patients taking levothyroxine treatment had a suppressed serum TSH.
14 The endogenous causes of subclinical hyperthyroidism are similar to causes of overt hyperthyroidism. Graves' disease is the most common cause in the young population, whereas toxic nodular goitre (solitary or multinodular) is common in the elderly population. 15 Some patients may have a transient biochemical picture of subclinical hyperthyroidism during treatment of overt hyperthyroidism or in cases due to thyroiditis of either autoimmune or viral aetiology.
Epidemiology
Epidemiological studies differ in the definition of a low serum TSH concentration and whether the subjects included were receiving levothyroxine therapy. The reported overall prevalence is ∼3%, with men and women over 65 years having the highest prevalence with 50% taking levothyroxine. In the National Health and Nutrition Examination Survey (NHANES III), the prevalence was highest in those subjects aged 20-39 years and those aged >79 years. 16 In this study, the percentage of subjects with serum TSH concentrations <0.4 mIU/l was significantly higher in women than in men, and black subjects had significantly lower mean serum TSH concentrations, and therefore a higher prevalence of subclinical hyperthyroidism (0.4%) than whites (0.1%) or Mexican Americans (0.3%). The prevalence of subnormal serum TSH concentrations is higher in iodinedeficient populations (6-10%), due to functional autonomy from nodular goitres. 17 
Progression
Among patients with subclinical hyperthyroidism, those with low but detectable serum TSH may recover spontaneously when re-tested. Data on risk of progression to overt hyperthyroidism are limited. In majority of subjects, a detectable below normal serum TSH will normalize. In those subjects with an undetectable serum TSH and a confirmed aetiology as determined by thyroid scintigraphy due to Graves' disease or nodular disease, it has been calculated that the annual incidence is ∼5-8%.
18 A large Scottish population study 19 followed up patients with at least two low serum TSH measurements for at least 4 months to up to 7 years. Few patients developed hyperthyroidism (0.5-0.7%) and percentage of those reverting to normal increased with time and this was more common in those with baseline serum TSH between 0.1 and 0.4 mIU/l.
Adverse outcomes
Triiodothyronine has an effect on the cardiac pacemaker and vascular smooth muscle through non-genomic and genomic actions and on myocardial contractility through myocardial structural and regulatory gene transcription. 20, 21 Although the resulting inotropic, chronotropic and lusitropic effects of excess thyroid hormones on the heart are more obvious in overt hyperthyroidism, they are present to a lesser extent in subclinical hyperthyroidism. Patients with subclinical hyperthyroidism have increased 24 h heart rate 22, 23 and increased frequency of atrial and ventricular ectopics. 22, 23 The frequency of atrial fibrillation (AF) is increased in patients with subclinical hyperthyroidism. In two large studies of the elderly population, there was reported 13% incidence of AF in subclinical hyperthyroidism compared with 2% in controls 24 and 9.5% versus 4.7% in controls. 25 Similar results were noted in other studies. 26, 27 The increase in cardiovascular or all cause mortality has been documented in some [28] [29] [30] but not all studies. 26, [31] [32] [33] A recent meta-analysis demonstrated that endogenous subclinical hyperthyroidism was associated with increased risk of total, coronary heart disease (CHD) mortality and incident AF. The highest risk of CHD mortality and AF is noted when serum TSH <0.10 mIU/l. 34 Thyroid hormone stimulates osteoclastic bone activity as evident in increased bone turnover and there is increased fracture risk in patients with overt hyperthyroidism. 35 There is evidence of decreased bone mineral density in post-menopausal women with subclinical hyperthyroidism, 36, 37 but little evidence in men or pre-menopausal women. In a large cohort of post-menopausal women aged 65 years or older, there was a fourfold increased risk of vertebral fractures and threefold higher risk of occurrence of hip fracture in patients with serum TSH <0.1 mIU/l. 38 In another study, of patients older than 65 years, the incidence of hip fracture was higher in men but not in women with subclinical hyperthyroidism than euthyroid patients. 39 There has been no evidence of symptoms or changes in mood or cognitive function in patients with subclinical hyperthyroidism in large populationbased cohorts. 28, 40, 41 In elderly people though, it has been associated with dementia in cross-sectional studies.
42-45
Treatment
Advocates of intervening for subclinical hyperthyroidism argue that early treatment might reduce mortality, prevent the later development of AF, osteoporotic fractures and overt hyperthyroidism. Other potential benefits of earlier treatment are relief of neuro-psychiatric symptoms and prevention of the long-term consequences of exposure of the heart muscle to excessive stimulation from thyroid hormones. A population-based 10-year cohort study in Birmingham, UK, found a higher mortality rate among patients who had low serum TSH initially. 46 The excess mortality was due primarily to higher mortality from cardiovascular diseases. A recent meta-analysis of selected population-based cohort studies has examined whether mild thyroid hormone increases CHD risk. For subclinical hyperthyroidism, there is little evidence of an association with CHD events or mortality. 47 The available treatment modalities for the treatment of subclinical hyperthyroidism are the same as for overt disease and include medical therapy with thionamides, radioiodine therapy and rarely surgery. 48 Different recommendations and position papers have been reported by various physician organizations. 6, 49, 50 No consensus exists regarding the treatment of subclinical hyperthyroidism, although it has been strongly argued without any evidence-base that therapy with anti-thyroid drugs or radioiodine may be indicated in view of the longterm risk of AF and loss of bone density. 50 Any potential benefits of therapy in subclinical hyperthyroidism must be weighed against the substantial morbidity associated with the treatment of thyrotoxicosis.
Subclinical hypothyroidism
Causes
A mildly increased serum TSH may be found either post-radioiodine therapy or post-surgery in up to 50% of apparently euthyroid patients and usually represents a stage in the progression towards overt thyroid failure. If present 1 year or more after radioiodine or surgical treatment, then the annual rate of progression to overt hypothyroidism after either treatment is 2-6%. Less common causes include external beam irradiation of malignant tumours of the head and neck, and drugs including lithium, amiodarone and interferon, undiagnosed Addison's disease and renal failure. Circulating antibodies against TSH or mouse immunoglobulins, when used as assay reagents, can also yield falsely raised TSH immunoassay readings. Thyroid hormone resistance and TSH-secreting pituitary tumours can present as an inappropriately elevated serum TSH but raised thyroid hormone levels. The causes of subclinical hypothyroidism are multiple and variable (Table 2) .
Chronic autoimmune thyroiditis is by far the commonest cause. In epidemiological surveys of iodine-replete communities, a mildly increased serum TSH (between 4 and 10 mIU/l) is associated with positive thyroid peroxidase (TPO) antibodies in 60-80% of subjects. In the original Whickham survey in Northeast England, 8% of women (10% of women over 55 years of age) and 3% of men had subclinical hypothyroidism. 3 In the Colorado study, 9.4% of the subjects had a high-serum TSH concentration, of which majority had subclinical hypothyroidism.
14 Among those with a high-serum TSH concentration, 74% had a value between 5.1 and 10 mIU/l and 26% had a value of >10 mIU/l. The percentage of subjects with a high-serum TSH concentration was higher for women than for men in each decade of age, and ranged from 4 to 21% in women and 3 to 16% in men. In NHANES III, serum TSH concentrations increased with age in both men and women and were higher in whites than in blacks, independent of serum anti-thyroid antibody concentrations. 16 Approximately 2% of adolescents aged 12-19 years had a serum TSH >4.5 mIU/l.
Progression
Spontaneous recovery has also been described in subjects with subclinical hypothyroidism, although frequency of this phenomenon is unclear. In one study, 37% of patients normalized their serum TSH levels over a mean follow-up of 32 months. 51 Normalization of serum TSH is more likely to occur in patients with negative anti-thyroid antibodies and serum TSH <10 mIU/l and within the first 2 years of diagnosis.
The 20-year follow-up of the Whickham cohort provided incidence data and allowed the determination of risk factors for spontaneous hypothyroidism in this period. 52 The mean annual incidence of spontaneous hypothyroidism during the 20-year follow-up period was 3.5 per 1000 and 0.6 per 1000 in surviving women and men, respectively. Either raised serum TSH or positive anti-thyroid antibodies alone or in combination were associated with a significantly increased risk of developing hypothyroidism. In the surviving women, the annual risk of spontaneous overt hypothyroidism was 4% in those who had both high-serum TSH and anti-thyroid antibody concentrations, 3% if only their serum TSH concentrations was high and 2% if only their serum anti-thyroid antibody concentration was high; at the time of follow-up, the respective rates of hypothyroidism were 55, 33 and 27%. The probability of developing hypothyroidism was higher in those women who had serum TSH concentrations >2.0 mIU/l and high-serum titres of anti-thyroid microsomal antibodies during the first survey. All studies indicate that the higher the serum TSH value, the greater the likelihood of development of overt hypothyroidism in subjects with chronic autoimmune thyroiditis (Table 3) . 
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The other incidence data for hypothyroidism are from short (and often small) follow-up studies. 53 In elderly subjects, the annual incidence rate of hypothyroidism varies widely between 0.2 and 7% in the available studies. Data from the large population study in Tayside 
Adverse effects
Subclinical hypothyroidism results in depressed systolic function and left ventricular diastolic dysfunction. 56 Vascular function can also be impaired in thyroid hormone deficiency. 57, 58 In the Whickham study, patients with subclinical hypothyroidism had higher systolic and diastolic blood pressure and total cholesterol. 59 Overt hypothyroidism is associated with increased total and low-density lipoprotein cholesterol. 60 But in subclinical hypothyroid patients, these changes may be present in certain patients only especially with serum TSH >10 mIU/l, 61,62 smokers 63 and insulin resistance. Subclinical hypothyroidism has been associated with increased risk of heart failure in the elderly population. 65, 66 The risk of cardiovascular and mortality was increased in some studies 31, 59, 67, 68 but not in all. 26, 30, 32, 66 Two recent meta-analyses of 10 population-based cohort studies have examined whether subclinical hypothyroidism increases CHD risk. 47, 69 The relative risks of CHD events and cardiovascular and overall mortality were 1.2, 1.2 and 1.1, respectively. Both analyses, however, suggest that the cardiovascular risk may be more significant in younger adults, approximately 1.5 vs. 1.0 for population with mean ages younger or older than 65 years, respectively. There is also evidence in the very elderly people that subclinical hypothyroidism may even be associated with longevity. 28, 70 In patients with subclinical hypothyroidism anxiety, symptoms of depression, impaired cognitive function and memory have been reported. [71] [72] [73] [74] [75] [76] [77] Subclinical hypothyroidism seems to be less symptomatic in the elderly population. 28, 56, 78, 79 Evidence of early mild thyroid failure is a relatively common finding in women with subfertility, although it is rarely an explanation for being unable to conceive. Meta-analyses of observational data indicate that pregnant women with subclinical hypothyroidism have an increased risk of adverse pregnancy outcome. 80 Subclinical hypothyroidism increases the odds of pregnancy complications, including preeclampsia, placental abruption, preterm birth and neonatal mortality. 81 While there is evidence to suggest that subclinical hypothyroidism in early pregnancy may also be associated with impaired intellectual and psychomotor development [81] [82] [83] [84] and that this impairment may be prevented with levothyroxine treatment, 83, 84 this is not supported by a recent randomized control trial. 85 
Treatment
Most patients with subclinical hypothyroidism will have serum TSH levels between 5 and 10 mIU/l, normal free T4 levels and relatively few symptoms. And while some will progress to overt hypothyroidism, a significant proportion will revert to a normal serum TSH without treatment. No good trials of levothyroxine therapy for a persistently mildly increased serum TSH exist so patients can be reassured that they do not need treatment unless they are symptomatic, pregnant or pre-conception, aged <65 years or are older than 65 with heart failure. A study using data from UK General Practitioner Research Database concluded that treatment of subclinical hypothyroidism (TSH 5.01-10 mIU/l) was associated with fewer ischaemic heart disease events in younger individuals, but this was not evident in older people. 86 If the serum TSH >10 mIU/l, then levothyroxine is indicated. If the serum TSH is mildly increased between 4 and 10 mIU/l and the patient is anti-TPO antibody positive, an annual check of serum TSH is recommended with the commencement of levothyroxine, once the serum TSH increases to >10 mIU/l. If the patient is thyroid antibody negative, then ensuring a check of serum TSH every 3-5 years is all that is required. If the patient with a serum TSH of 4-10 mIU/l has symptoms consistent with hypothyroidism and the TSH elevation persists, then a 3-6 month therapeutic trial of levothyroxine appears justified. If the patient feels improved by therapy, it is reasonable to continue treatment. If the patient does not have symptoms and the serum TSH level appears stable with positive anti-TPO antibodies, the annual risk of progression to overt hypothyroidism is 4% per year and so an annual serum TSH surveillance strategy is warranted. If the TPO antibodies are negative, then 3-yearly serum TSH surveillance is recommended, with the risk of progression to overt hypothyroidism 3% per year.
The exception to the above is in neonates and children, pregnancy or in someone trying to conceive, when a mildly increased serum TSH should always be treated as it is associated with adverse outcomes for both mother and foetus. These women should be given levothyroxine to ensure that the serum TSH is normal prior to conception and the dose adjusted to ensure that the serum TSH is not higher than 2.5 mIU/l prior to conception. In treated hypothyroid women, the serum TSH may rise during pregnancy and they will require an extra 25-50 µg daily during the first 4-8 weeks of pregnancy. Following delivery, women should be advised to decrease the levothyroxine dosage to their pre-pregnancy dose.
Conclusions
Subclinical thyroid disease is a common problem. The majority of patients remain asymptomatic. There has been increased identification of cases due to increased awareness and regular routine testing of patients. The screening of general population is currently not recommended. There is also lack of agreement for treating asymptomatic people with subclinical thyroid disease, although there is general consensus for intervention in specific subgroups like pregnant women and the elderly. There remains a need for large randomized clinical trial for identification of high-risk cases needing intervention and the impact of these interventions in long morbidity and mortality.
